Additionally, Su et al. [24] reported the significant benefit of adjuvant RT in 43 carriers of germline ATM mutations diagnosed with breast cancer; they reported that 13 patients treated with RT (not cobalt therapy) remained locally disease-free, sustaining tolerable toxicities. This evidence concerns the gene ATM and breast carcinoma.